SEARCH

SEARCH BY CITATION

References

  • 1
    Hanto DW, Frizzera G, Purtilo DT et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 42534261.
  • 2
    Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematology Workshop. Semin Diagn Pathol 1997; 14: 814.
  • 3
    Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997; 2: 3340.
  • 4
    Aris RM, Maia DM, Neuringer IP et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 17121717.
  • 5
    Walker RC, Paya CV, Marshall WF et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214221.
  • 6
    Hanto DW, Frizzera G, Gajl-Pecsalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461472.
  • 7
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factors in analysis in a single centre. Transplantation 1993; 56: 8896.
  • 8
    Ho M, Miller G, Atchison RW et al. Epstein-Barr virus infections and DNA hybridization studies in postransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876886.
  • 9
    Birkeland SA, Anderson HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 67: 12091214.
  • 10
    Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97103.
  • 11
    McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 16041611.
  • 12
    Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848852.
  • 13
    Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547554.
  • 14
    Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 1995; 59: 135138.
  • 15
    Biron KK, Stanat SC, Sorrell JB et al. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl} guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985; 82: 24732477.
  • 16
    Kremers HM, Funch DP, Robson RA et al. A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiol Drug Saf 1999; 8: 509518.
  • 17
    Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 14621467.
  • 18
    Muti G, Cantoni S, Oreste P et al. Cooperative Study Group on PTLDs. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 6777.
  • 19
    Shahinian VB, Muirhead N, Jevnikar AM et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851856.
  • 20
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222230.
  • 21
    Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy 2003; 5: 323335.
  • 22
    Hopwood PA, Brooks L, Parratt R et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002; 74: 194202.
  • 23
    Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 2000; 182: 10131021.
  • 24
    Babel N, Schwarzmann F, Pruss A, Volk HD, Reinke P. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplant Proc 2004; 36: 26792682.
  • 25
    Razonable RR, Paya CV. Herpresvirus infections in transplant recipients: current challenges in the cliical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10: 6065.
  • 26
    Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 2944.
  • 27
    Khatri V, Baiocchi RA, Peng R et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 1999; 163: 500506.
  • 28
    Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 14621470.
  • 29
    Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997; 350: 17291733.
  • 30
    Winston DJ, Busuttil RW. Randomised controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004; 77: 305308.
  • 31
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.